CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
Kim Benda, who sought to challenge incumbent Mayor Mike Parkinson, was removed from the ballot on Monday morning after her petition papers were found to be unbound — a technical violation that ...
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug ...
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.